

+ HEALTH TO YOUR WEALTH.








INVEST IN YOUR HEALTH



WHY INVEST IN INDIAN HEALTHCARE

- By 2030 India will be one of the top 3 pharma markets
- 40% lower labour cost
- Highest number of US FDA approved facilities
- Expected earnings recovery over next 6-12 months, leading to re-rating of the sector






HEALTH TIP#2


ADD MULTIVITAMINS TO YOUR DIET TO BOOST GROWTH & IMMUNITY

GROWTH BOOSTERS IN FOREIGN MARKETS



Domestic Pharma Mkt. Share MNC Pharma Mkt. Share

US revenue from Indian pharma companies







WATCH YOUR WEIGHT



PORTFOLIO WEIGHTS

	THEME CATEGORY	Portfolio Weight	Benchmark Weight
	Domestic focused companies (Export investments to provide upside)	30%-40%	25%
Thyrocare Encoments	Diagnostic Laboratories (Competitive intensity stabilizing)	up to 10%	1%
Nonis Strong	Hospitals (Price regulation concern, volume growth to continue)	up to 10%	5%
	Health Insurance (Exponential secular growth ahead)	up to 10%	0%
Syngene	Contract research and manufacturing (Huge opportunity and limited scalable competitors)	5%-15%	8%
	Export focused pharma companies (US pricing cycle bottoming out and China opening up)	10%-20%	34%
6 SIX glenmark	Evolving generic companies [*] (Innovation investments - long-term secular growth)	10%-20%	26%
۹	US Healthcare (Secular and profitable growth trajectory)	up to 25%	0%

⁶We are overweight the theme except Sun Pharma (18% weight in benchmark).⁶ Please note the stocks names mentioned are provided for illustrative purpose. The sector(s)(stock(s)(ssuer(s) mentioned in this presentation do not constitute any research report/recommendation of the same and the Fund many or may not have any future position in these sector(s)(stock(s)(ssuer(s) mentioned in the fund many or may not have any future position in these sector(s)(stock(s)(ssuer(s) mentioned in the fund many or may not have any future position in these sector(s)(stock(s)(ssuer(s) mentioned in the fund many or may not have any future position in these sector(s)(stock(s)(ssuer(s) mentioned in the fund many or may not have any future position in these sector(s)(stock(s)(ssuer(s) mentioned in the fund many or may not have any future position in these sector(s)(stock(s)(ssuer(s) mentioned in the future may or may not have any future position in these sector(s)(stock(s)(ssuer(s) mentioned in the future may or may not have any future position in these sector(s)(stock(s)(ssuer(s) mentioned in the future may or may not have any future position in the sector(s)(stock(s)(ssuer(s) mentioned in the future may or may not have any future position in the sector(s)(stock(s)(stock(s))(ssuer(s) mentioned in the sector(s)(stock(s)(stock(s))(ssuer(s) mentioned in the sector(s)(stock(s)





EAT OFTEN AND CONTROL THE PORTION SIZE





FUND ALLOCATION

	DSP Healthcare Fund Portfolio	BSE Healthcare Index	Nifty Midcap 100	Peers Pharma Funds	
Avg. Market Cap (Rs. Cr.)	24,493	52,241	18,513	41,881	
PORTFOLIO BREAK-UP					
LARGE CAP	10 - 20%	67.1%	4.1%	46.4%	
MID CAP	30 - 40%	21.0%	93.5%	30.4%	
SMALL CAP	30 - 40%	1.9%	2.4%	18.2%	
US HEALTHCARE	up to 25%	-	-	-	

Source: IMPACT, FactSet. Data as on September 2018. The above range and portfolio construct is only indicative and the Scheme may or may not invest in the same range depending on the market condition & other macro factors





REDUCE STRESS BY LIVING A BALANCED LIFE



THE BALANCE THAT INDIAN AND US MARKETS CREATE

	10 Years CAGR	Standard Deviation
BSE Healthcare TRI	18.89%	16.60%
DJ US Healthcare Index	19.36%	15.93%
75% BSE Healthcare TRI + 25% DJ US Healthcare Index	19.01%	13.68%

Low correlation (0.33) between US & India Healthcare can help consistency of returns

Source: Bloomberg, Period considered is from Jan 2009 to Sep 2018. Past performance may or may not sustain in future and should not be used as a basis for comparison with other investments. These figures pertain to performance of the index and do not in any manner indicate the returns/performance of the Scheme.





UNDERSTAND YOUR PHYSICAL LIMITATIONS



KEY RISK



SHOULD NOT INVEST IF YOU HAVE








TAKE PRESCRIBED MEDICATION ON TIME, DILIGENTLY



THE PRESCRIBED WAY OF INVESTING

SIP/STP

It is the best way to use volatility to your advantage.










AVOID SELF MEDICATION



NFO Period: Nov 12 to Nov 26, 2018



Disclaimer for Logos/Trademarks: All other product or company names, logos, icons, graphics or designs referred to in this document are the trademarks and/or service marks of their respective owners and are exhibited only in such a manner as is intended to be for the benefit of such owners and the Owner intends no infingement of such trademarks and/or service marks in any manner whatsoever. The appearance or absorace of any brid party's trade names, trademarks or service marks on the document does not imply any endorsement or non-endorsement thereof by the Owner. All rights not expressly granted herein are reserved by the Owner.

Asset Allocation :Under normal circumstances, it is anticipated that the asset allocation of the Scheme shall be as follows:

A. Equity and equity related securities of pharmaceutical and healthcare companies: 80% to 100%

B. Equity and Equity related securities of other Companies: 0% to 20%

C. Debt, securitized debt and Money Market Securities: 0% to 20%

D.Units issued by REITs & InvITs: 0% to 10%

Past performance may or may not be sustained in the future There is no assurance of any capital protection/capital guarantee/neum to the investors in the Scheme. Investors are advised to consult their own legal, tax and financial advisors to determine possible tax, legal and other financial implication or consequence of subscribing to the units of the Fund. For Scheme specific risk factors please refer the Scheme Information Document (SID). For further details, please refer the Statement of Additional Information, SID and Key Information Memorandum cum Application Forms of the Scheme, which are available at AMC and Registrat Offices and Investor Service Centre[AMC website u: www.sbpirn.com.

The S&P BSE 100, S&P BSE 200, S&P BŠE Small Cap Index, S&P BSE Teck, S&P BSE Metak, S&P BSE Oli and Gas & S&P BSE SENSEX are product of Asia Index Private Limited, which is a pint venture of S&P Dow Jones Indexes LLC or its affliates ("SPDII") and BSE, and has been licensed for use by DSP Investment Mnagers PA: Ltd. Standard & Pooris® and S&P® are registered trademarks of Standard & Pooris Financial Services LLC ("S&P"). BSE® is a registered trademark of BSE Limited ("BSE"); and Dow Jones® a registered trademark of BSE Ministed ("BSE"); and Dow Jones® a registered trademark of BSE Limited ("BSE"); and Dow Jones® a registered trademark of BSE Limited ("BSE"); and Dow Jones® a registered trademark of BSE Minister ("Standard & Boris"); and Dow Jones® a registered trademark of BSE Limited ("BSE"); and Dow Jones® a registered trademark of BSE Limited ("BSE"); and Dow Jones® a registered trademark of BSE Minister ("Standard & Boris"); and Dow Jones® a registered trademark of BSE Limited ("BSE"); and Dow Jones® a registered trademark of BSE Minister ("Standard & Boris"); and Dow Jones® a registered trademark of BSE Minister ("Standard & Boris"); and Dow Jones® a registered trademark of BSE Limited ("BSE"); and Dow Jones® a registered trademark of BSE Minister ("Standard & Boris"); and Dow Jones® a registered trademark of BSE Minister ("Standard & Boris"); and Dow Jones® a registered trademark of BSE Limited ("BSE"); and Dow Jones® a registered trademark of BSE Minister ("Standard & Boris"); and Dow Jones® a registered trademark of BSE Limited ("BSE"); and Dow Jones® a registered trademark of Dow Jones® a registered trademark of BSE Limited ("BSE"); and Dow Jones® a registered trademark of BSE Limited ("BSE"); and Dow Jones® a registered trademark of BSE Limited ("BSE"); and Dow Jones® a registered trademark of BSE Limited ("BSE"); and Dow Jones® a registered trademark of BSE Limited ("BSE"); and Dow Jones® a registered trademark of BSE Limited ("BSE"); and DSE Limited ("BSE"); and DSE Limited ("BSE"); and DSE Limited